and don’t forget about Neurocrine. When Indiplon was stalled by the FDA their stock tanked more than 50%. Then Pfizer dumped them as a partner and now Neurocrine is left with very little. Neurocrine hired a whole new salesforce (>100) to push Indiplon and now they are all out of work. Indiplon was going to be their revenue stream to fund internal research projects. Now Neurocrine is left with the choice of sinking all of their money into re-developing Indiplon or financing early stage research. They can’t sell Indiplon because the only buyer (Pfizer) walked away. Whatever the case may be Neurocrine is a long way off from revenue and profitability.
